Should You Buy Archer Aviation Below $6?

Archer Aviation, trading below $6 per share, is expanding beyond passenger eVTOLs through an autonomous aircraft platform co-developed with Anduril and planned acquisitions of Boeing's Insitu and Wisk businesses. Insitu generates roughly $200 million in annual revenue, about 29 times Archer's approximately $7 million trailing-12-month revenue, while Wisk could add autonomous eVTOL technology that may reduce future pilot costs. The upside remains highly speculative: Archer is burning cash, has no meaningful current revenue base, and still requires FAA certification and scalable manufacturing capabilities.

Analysis

The strategic value is not the headline revenue multiple; it is whether ACHR can convert acquired defense capability into funded programs that absorb fixed engineering and manufacturing overhead. A defense revenue stream could lower the market’s probability-weighted cash-burn discount and extend the funding runway, but only if it carries contract backlog, acceptable working-capital terms, and retention of critical personnel. Without disclosed purchase price, financing, backlog, and margin data, the transaction should be treated as a potential dilution event rather than an immediate earnings catalyst.

Near term, ACHR is likely to trade on deal-close details and financing rather than operational progress. The key 1-3 month catalysts are definitive transaction documents, evidence of non-dilutive government funding, and any revision to cash-use guidance; a cash raise at a meaningful discount would likely overwhelm the strategic narrative. Over 6-18 months, defense sales can diversify certification risk, but they do not solve the more important commercial valuation question: whether aircraft production can reach repeatable unit economics before cash resources require another equity issuance.

The non-obvious competitive effect is that a defense-oriented platform may place ACHR in competition for autonomous-aircraft procurement dollars with AVAV, KTOS and privately held defense-drone suppliers, where procurement credibility and supply-chain security matter more than eVTOL design aesthetics. BA could benefit modestly if asset sales reduce non-core development spend and crystallize value, but any material upside depends on consideration and liability transfer, neither of which is established. Consensus is apt to capitalize hypothetical pilot-cost savings too early: fully autonomous passenger operations require a substantially higher regulatory and public-acceptance threshold than piloted certification, making that benefit a long-duration option rather than a base-case cash-flow assumption.

Key Decisions for Investors

• Do not initiate a core long in ACHR before definitive acquisition terms and financing are disclosed. Set an event-driven alert for purchase consideration, assumed liabilities, annual backlog, EBITDA/FCF profile, and pro forma cash runway; a cash-funded or heavily discounted equity deal would invalidate the near-term bullish case.
• For high-risk capital only, consider a small ACHR starter position after deal terms confirm no material near-term dilution, with a 3-6 month horizon into defense-contract or certification milestones. Size as venture-style exposure; exit on a material increase in quarterly cash burn, reduced liquidity runway below 12 months, or adverse certification-timeline guidance.
• Prefer a relative-value expression of long AVAV or KTOS versus ACHR if defense-autonomy enthusiasm broadens without funded awards. AVAV and KTOS have existing procurement channels and revenue bases; cover the short leg if ACHR announces a large, funded multi-year program or transaction economics demonstrate accretive cash flow.
• Keep BA on watch rather than buy on the asset-sale narrative. Reassess only after disclosed proceeds and indemnity/liability terms show a meaningful reduction in cash obligations; absent that, the financial impact is unlikely to move BA’s broader delivery, certification, and balance-sheet valuation drivers.